Dr. Jenny Zilberberg brings more than 20 years of experience across academia and the biotechnology sector, with a focus on translational immunology and cancer immunotherapy. She previously served as Head of Research at Imvax, where she led preclinical and translational efforts for the company’s Goldspire® immunotherapy platform and its lead product, IGV-001, for newly diagnosed glioblastoma. She is a member of the Scientific Advisory Board of FIG Therapeutics and partners with pre-seed and early-stage companies in the immunotherapy space.

Dr. Zilberberg received her M.S. and Ph.D. in bioengineering from Penn State University and her B.S. in chemical engineering from Universidad Simón Bolívar, Venezuela. She is an inventor of patents covering ex vivo culture platforms designed to study bone and bone marrow niches and has authored numerous peer-reviewed publications. Her work has been supported by NIH-funded grants focused on graft-versus-host disease and on developing New Approach Methodologies to investigate the tumor microenvironment of both solid and hematologic malignancies. Jenny has previously held positions as an Associate Member at the Center for Discovery and Innovation, part of Hackensack Meridian Health, as well as adjunct faculty appointments in the Department of Chemistry and Chemical Biology at Stevens Institute of Technology and at Georgetown University School of Medicine.